• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Sinovac Biotech, Ltd.

    6/18/25 2:09:19 PM ET
    $SVA
    Major Pharmaceuticals
    Health Care
    Get the next $SVA alert in real time by email
    6-K 1 tm2518308d1_6k.htm FORM 6-K

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

    THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of June 2025

     

     

    Commission File Number: 001-32371

     

     

    SINOVAC BIOTECH LTD.

     

    No. 39 Shangdi Xi Rd, Haidian District

    Beijing 100085, People’s Republic of China

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    Form 20-F    x          Form 40-F    ¨

     

     

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      SINOVAC BIOTECH LTD.
         
      By: /s/ Chiang Li
      Name: Dr. Chiang Li
      Title: Chairman of the Board of Directors

     

    Date: June 18, 2025

     

     

     

     

    Exhibit Index

     

    Exhibit 99.1   Notice and Proxy Statement for the Company’s Special Meeting of Shareholders to be held on July 8, 2025
         
    Exhibit 99.2   Form of Proxy Card for the Company’s Special Meeting of Shareholders to be held by July 8, 2025

     

     

     

     

    Get the next $SVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SVA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SINOVAC Board of Directors Prevails Against Advantech/Prime's New York Lawsuit

      New York Court Denies Advantech/Prime's Petition for Emergency Injunctive Relief Clears Legal Hurdle for Dividend Paying Agent to Payout the Special Cash Dividend of US$55.00 Per Common Share on July 7, 2025 SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it has prevailed against Advantech/Prime Success' ("Advantech/Prime") Petition for Emergency Injunctive Relief in the U.S. District Court for the Southern District of New York. The result in the New York court represents another failure in the campaign by Advantech/Prime in coordination with Vivo Capital (together known as the "Dissenting Inves

      6/20/25 10:56:00 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SINOVAC Board of Directors Files Definitive Proxy Materials

      Files definitive proxy statement and mails letter to shareholders Urges shareholders to VOTE the WHITE proxy card and vote "AGAINST" the misguided proposals to remove SINOVAC's Board and appoint the Reconstituted Imposter Former Board Slate The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced it has filed its definitive proxy materials with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). In conjunction with t

      6/18/25 2:18:00 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SINOVAC Announces New Board Member

      Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that it received a resignation notice from David Guowei Wang, a member of the board of directors (the "Board") and a member of the Audit Committee, Compensation Committee and the Corporate Governance and Nominating Committee of the Board, effective immediately. Mr. Wang's resignation was due to increased professional commitments and time constraints and was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Board has appointed Geoffrey C. Hsu, CFA, as a director to the Boar

      6/18/25 4:38:00 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care

    $SVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

      SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

      9/12/24 4:03:46 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Sinovac Biotech, Ltd.

      SC 13D/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

      6/17/24 4:02:44 PM ET
      $SVA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Sinovac Biotech, Ltd. (Amendment)

      SC 13G/A - SINOVAC BIOTECH LTD (0001084201) (Subject)

      3/20/24 7:33:23 AM ET
      $SVA
      Major Pharmaceuticals
      Health Care